Pfizer Director Shantanu Narayen Receives $50K Phantom Share Award

What Happened
Shantanu Narayen, a member of Pfizer's Board of Directors, was granted 1,743.983 units (phantom shares) on 2026-09-25 as a director award valued at $50,000. The filing lists an imputed price of $28.67 per unit. This transaction is an award/compensation grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-25; Form 4 filed: 2026-09-29 (timely filing).
• Units granted: 1,743.983 phantom-share units; imputed price/value: $28.67 per unit; total value reported: $50,000.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — each unit equals one phantom share of common stock. F2 — units are deferred director compensation (including dividend equivalents) and are settled in cash or common stock at the director’s election following retirement.
• Transaction type: Award/grant (derivative); code A.

Context
This was a routine director compensation award (phantom units) rather than a market purchase or sale, so it primarily reflects standard board pay practices and not an immediate trading signal. The units are deferred and will convert to cash or equity only at retirement per the footnote, so there is no immediate change in market-held shares.